IL7 and neoplasm: In one study, MSCs were manipulated to deliver IL-7 and IL-12 to the tumor sites that enhance CAR-T response and anti-tumor activity by changing the profile of chronic inflammatory Th2 into Th17/Th1 profile which leads to longer-lasting anti-tumor CAR-T cells response (Haabeth et al., 2011[39]; Shalapour and Karin, 2015[106]).